Lone Gothard

Lone Gothard

Auto-generated profile, based on publicly available information

Lone Gothard

Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
EDEllen Donovan
Ellen Donovan
NBNatalie Bleakley
Natalie Bleakley
EDErica Denholm
Erica Denholm
PEPhilip M evans
Philip M evans
LGLone Gothard
Lone Gothard
JYJohn Yarnold
John Yarnold

1 July 2002 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
BSBeatrice Seddon
Beatrice Seddon
ACAudrey Cook
Audrey Cook
LGLone Gothard
Lone Gothard
ESEmma Salmon
Emma Salmon
KLKate Latus
Kate Latus
JYJohn Yarnold
John Yarnold

12 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GOGráinne O’bRien
Gráinne O’bRien
LCLourdes Cruz-Garcia
Lourdes Cruz-Garcia
MMMatthäus Majewski
Matthäus Majewski
JGJakub Grepl
Jakub Grepl
MAMichael Abend
Michael Abend
Christophe BadieChristophe Badie
Christophe Badie
Previous investigations in gene expression changes in blood after radiation exposure have highlighted its potential to provide biomarkers of exposure. Here, FDXR transcriptional changes in blood were investigated in humans undergoing a range of external radiation exposure procedures covering several orders of magnitude (cardiac fluoroscopy, diagnostic computed tomography (CT)) and treatments (total body and local radiotherapy). Moreover, a method was developed to assess the dose to the blood using physical exposure parameters. FDXR expression was significantly up-regulated 24 hr after radiotherapy in most patients and continuously during the fractionated treatment. Significance was reached even after diagnostic CT 2 hours post-exposure. We further showed that no significant differences in expression were found between ex vivo and in vivo samples from the same patients. Moreover, potential confounding factors such as gender, infection status and anti-oxidants only affect moderately FDXR transcription. Finally, we provided a first in vivo dose-response showing dose-dependency even for very low doses or partial body exposure showing good correlation between physically and biologically assessed doses. In conclusion, we report the remarkable responsiveness of FDXR to ionising radiation at the transcriptional level which, when measured in the right time window, provides accurate in vivo dose estimates.

1 November 2004 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
LGLone Gothard
Lone Gothard
PCPaul Cornes
Paul Cornes
JEJudith Earl
Judith Earl
EHEmma Hall
Emma Hall
JMJulie MacLaren
Julie MacLaren
JYJohn Yarnold
John Yarnold

1 March 2001 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JPJoyce Pritchard
Joyce Pritchard
PAPraveen Anand
Praveen Anand
JBJon Broome
Jon Broome
CDCarol Davis
Carol Davis
LGLone Gothard
Lone Gothard
JYJohn R Yarnold
John R Yarnold

1 February 2016 in The Lancet Oncology
Verified
Journal Article
Open access
MGMark Glover
Mark Glover
GSGary R Smerdon
Gary R Smerdon
HAH Jervoise Andreyev
H Jervoise Andreyev
BBBarbara E Benton
Barbara E Benton
PBPieter Bothma
Pieter Bothma
JYJohn Yarnold
John Yarnold
Hyperbaric oxygen has been used as a therapy for patients experiencing chronic intestinal syndromes after pelvic radiotherapy for decades, yet the evidence to support the use of this therapy is based almost exclusively on non-randomised studies. We aimed to provide conclusive results for the clinical benefits of hyperbaric oxygen in patients with chronic bowel dysfunction after radiotherapy for pelvic malignancies. HOT2 was a double-blind, sham-controlled, phase 3 randomised study of patients (≥18 years) with chronic gastrointestinal symptoms for 12 months or more after radiotherapy and which persisted despite at least 3 months of optimal medical therapy and no evidence of cancer recurrence. Participants were stratified by participating hyperbaric centre and randomly assigned (2:1) by a computer-generated list (block size nine or 12) to receive treatment with hyperbaric oxygen therapy or sham. Participants in the active treatment group breathed 100% oxygen at 2·4 atmospheres of absolute pressure (ATA) and the control group breathed 21% oxygen at 1·3 ATA; both treatment groups received 90-min air pressure exposures once daily for 5 days per week for a total of 8 weeks (total of 40 exposures). Staff at the participating hyperbaric medicine facilities knew the allocated treatment, but patients, clinicians, nurse practitioners, and other health-care professionals associated with patients' care were masked to treatment allocation. Primary endpoints were changes in the bowel component of the modified Inflammatory Bowel Disease Questionnaire (IBDQ) score and the IBDQ rectal bleeding score 12 months after start of treatment relative to baseline. The primary outcome was analysed in a modified intention-to-treat population, excluding patients who did not provide IBDQ scores within a predetermined time-frame. All patients have completed 12 months of follow-up and the final analysis is complete. The trial is registered with the ISRCTN registry, number ISRCTN86894066. Between Aug 14, 2009, and Oct 23, 2012, 84 participants were randomly assigned: 55 to hyperbaric oxygen and 29 to sham control. 75 (89%) participants received 40 pressure exposures, all participants returned the IBDQ at baseline, 75 (89%) participants returned the IBDQ at 2 weeks post-treatment, and 79 (94%) participants returned the IBDQ at 12 months post-start of treatment. Patients were excluded from analyses of co-primary endpoints if they had missing IBDQ scores for intestinal function or rectal bleeding at baseline or at 12 months. In an analysis of 46 participants in the active treatment group and 23 participants in the control group, we found no significant differences in the change of IBDQ bowel component score (median change from baseline to 12 months of 4 (IQR -3 to 11) in the treatment group vs 4 (-6 to 9) in the sham group; Mann-Whitney U score 0·67, p=0·50). In an analysis of 29 participants in the active treatment group and 11 participants in the sham group with rectal bleeding at baseline, we also found no significant differences in the change of IBDQ rectal bleeding score (median change from baseline to 12 months of 3 [1 to 3] in the treatment group vs 1 [1 to 2] in the sham group; U score 1·69, p=0·092). Common adverse events in both groups were eye refractive changes (three [11%] of 28 patients in the control group vs 16 [30%] of 53 patients in the treatment group), increased fatigue (three [11%] vs two [4%]), and ear pain (six [21%] vs 15 [28%]). Eight serious adverse events were reported in eight patients: two were reported in two patients in the control group (tonsillitis requiring surgery [grade 3]; recurrent cancer of the vulva [grade 4]) and six serious adverse events were reported in six patients in the treatment group (malignant spinal cord compression requiring surgery [grade 3]; malignant paraortic lymph node involvement requiring surgery [grade 3]; recurrence of vomiting and dehydration [grade 3]; diarrhoea and fever associated with Campylobacter infection [grade 3]; recurrence of abdominal pain, bloating, diarrhoea, and urinary tract infection [grade 3]; aneurysm [grade 4]), none of which were deemed treatment-related. We found no evidence that patients with radiation-induced chronic gastrointestinal symptoms, including those patients with rectal bleeding, benefit from hyperbaric oxygen therapy. These findings contrast with evidence used to justify current practices, and more level 1 evidence is urgently needed. Cancer Research UK and National Health Service (NHS) funding to the National Institute of Health Research Biomedical Research Centre at The Royal Marsden and the Institute of Cancer Research.